GigaGen develops new class of drugs to treat Covid-19

US-based biotechnology company GigaGen has developed a new class of drugs, called recombinant hyperimmunes, to potentially treat patients with Covid-19.

August 11, 2020

US-based biotechnology company GigaGen has developed a new class of drugs, recombinant hyperimmunes, to potentially treat patients with Covid-19.

Hospitals across the country are using convalescent plasma to treat Covid-19. Obtained from people who recovered from the disease, convalescent plasma contains antibodies that could fight the infection.

However, plasma from many donors has weak antibody levels, limiting the manufacture of high-potency doses required to tackle the Covid-19 pandemic.

To address this, GigaGen developed a technology that could enable millions of doses of polyclonal antibody therapeutics from survivors with good levels of antibodies.

The company’s lead investigational candidate GIGA-2050 was created after screening 50 convalescent Covid-19 donors. Recombinant hyperimmunes consist of thousands to tens-of-thousands of antibodies

These new class of drugs derived from donor B cells generated recombinantly at large scale in mammalian cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new drugs work similarly to recombinant convalescent serum, which combines the benefits of recombinant antibodies with those of plasma-derived antibodies. GigaGen’s technology eliminates the need for more convalescent donors.

GigaGen co-founder and CEO David Johnson said: “Our approach only requires a few donors to generate enough product to treat millions of people. No other company on Earth has the technology to produce this kind of drug.

“We still don’t know whether vaccines and monoclonal antibodies will fail to prevent serious Covid-19, so our technology fills a critical niche to address the risk of a further escalating pandemic.”

The company added that the GIGA-2050 drug candidate, made up of a mixture of 12,500 anti-coronavirus antibodies, demonstrated greater IgG purity compared to plasma-derived drugs.

SARS CoV-2 live virus neutralisation assays found the drug candidate to be 100 times more protective than high-titer Covid-19 convalescent plasma.

GIGA-2050 can bind to different natural SARS CoV-2 variants, as well as its predecessor SARS CoV, indicating the drug candidate’s potential for broad efficacy.

The company published its new research in bioRxiv.

More Relevant

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close